collection
MENU ▼
Read by QxMD icon Read
search

LES

shared collection
49 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28054130/posterior-reversible-encephalopathy-syndrome
#1
REVIEW
Marlene Fischer, Erich Schmutzhard
The posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub)acute onset characterized by varied neurological symptoms, which may include headache, impaired visual acuity or visual field deficits, disorders of consciousness, confusion, seizures, and focal neurological deficits. In a majority of patients the clinical presentation includes elevated arterial blood pressure up to hypertensive emergencies. Neuroimaging, in particular magnetic resonance imaging, frequently shows a distinctive parieto-occipital pattern with a symmetric distribution of changes reflecting vasogenic edema...
January 4, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28039419/cumulative-immunosuppressant-exposure-is-associated-with-diversified-cancer-risk-among-14-832-patients-with-systemic-lupus-erythematosus-a-nested-case-control-study
#2
Chung-Yuan Hsu, Ming-Shyan Lin, Yu-Jih Su, Tien-Tsai Cheng, Yu-Sheng Lin, Ying-Chou Chen, Wen-Chan Chiu, Tien-Hsing Chen
OBJECTIVES: Immunosuppressive therapy is necessary to alter the natural course of SLE. However, immunosuppressant-related cancer risk is a major concern. The aim of this study was to determine whether immunosuppressant use is associated with cancer risk in SLE. METHODS: We designed a retrospective nested case-control study within an SLE population based on the National Health Insurance Research Database in Taiwan. We screened 14 842 patients with SLE from 2001 to 2013 and compared patients with SLE complicated by later cancer with patients with SLE but without cancer...
December 30, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013208/it-hasn-t-gone-away-the-problem-of-glucocorticoid-use-in-lupus-remains
#3
Diane Apostolopoulos, Eric F Morand
The treatment of SLE remains complex, and management is constrained by a lack of safe, effective, targeted therapies. Physicians, also, are constrained by a lack of evidence-based approaches with existing agents, including glucocorticoids, utilized in the majority of patients. While Cushingoid side effects of glucocorticoids are widely recognized, emerging literature now suggests that glucocorticoid use actually contributes to harmful outcomes in SLE, over and above these effects. These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013206/systemic-lupus-erythematosus-diagnosis-and-management
#4
REVIEW
Bernard Thong, Nancy J Olsen
SLE presents many challenges for clinicians. The onset of disease may be insidious, with many different symptoms and signs, making early and accurate diagnosis challenging. Tests for SLE in the early stages lack specificity; those that are useful later often appear only after organ damage is manifest. Disease patterns are highly variable; flares are not predictable and not always associated with biomarkers. Children with SLE may have severe disease and present special management issues. Older SLE patients have complicating co-morbid conditions...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/27992698/effects-of-hydroxychloroquine-on-cutaneous-lupus-erythematosus-a-multi-center-double-blind-randomized-parallel-group-trial
#5
N Yokogawa, H Eto, A Tanikawa, T Ikeda, K Yamamoto, T Takahashi, H Mizukami, T Sato, N Yokota, F Furukawa
Objectives To assess the efficacy and tolerability of hydroxychloroquine (HCQ) in a phase III clinical trial conducted in Japan Methods A double-blind randomized parallel-group clinical trial was performed. This was a baseline-controlled study and the group differences were evaluated in an exploratory analysis. A total of 103 patients with active CLE (CLASI activity score ≥4) were included. Patients were randomized (3:1) to receive HCQ or placebo in the 16-week double-blind period, and all patients were given HCQ in the following 36-week single-blind period...
December 19, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27307107/systemic-lupus-erythematosus-still-a-challenge-for-physicians
#6
REVIEW
A A Bengtsson, L Rönnblom
Systemic lupus erythematosus (SLE) has a complex clinical picture, and a number of defects in the immune system have been described in patients with the disease. Most organs can be involved in SLE, and in addition to the typical major organ manifestations (e.g. from kidneys and the central nervous system), early cardiovascular disease is a major determinant of prognosis. Several important findings during the last decade have increased the understanding of the mechanisms behind the disease characteristics and the underlying autoimmune process...
January 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/27637120/diagnosis-and-treatment-of-atrial-fibrillation
#7
Cecilia Gutierrez, Daniel G Blanchard
Atrial fibrillation is a supraventricular arrhythmia that adversely affects cardiac function and increases the risk of stroke. It is the most common arrhythmia and a major source of morbidity and mortality; its prevalence increases with age. Pulse rate is sensitive, but not specific, for diagnosis, and suspected atrial fibrillation should be confirmed with 12-lead electrocardiography. Because normal electrocardiographic findings do not rule out atrial fibrillation, home monitoring is recommended if there is clinical suspicion of arrhythmia despite normal test results...
September 15, 2016: American Family Physician
https://www.readbyqxmd.com/read/27872476/new-insights-into-the-immunopathogenesis-of-systemic-lupus-erythematosus
#8
REVIEW
George C Tsokos, Mindy S Lo, Patricia Costa Reis, Kathleen E Sullivan
The aetiology of systemic lupus erythematosus (SLE) is multifactorial, and includes contributions from the environment, stochastic factors, and genetic susceptibility. Great gains have been made in understanding SLE through the use of genetic variant identification, mouse models, gene expression studies, and epigenetic analyses. Collectively, these studies support the concept that defective clearance of immune complexes and biological waste (such as apoptotic cells), neutrophil extracellular traps, nucleic acid sensing, lymphocyte signalling, and interferon production pathways are all central to loss of tolerance and tissue damage...
November 22, 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27821390/update-on-lupus-nephritis
#9
Salem Almaani, Alexa Meara, Brad H Rovin
SLE is a chronic inflammatory disease that affects the kidneys in about 50% of patients. Lupus nephritis is a major risk factor for overall morbidity and mortality in SLE, and despite potent anti-inflammatory and immunosuppressive therapies still ends in CKD or ESRD for too many patients. This review highlights recent updates in our understanding of disease epidemiology, genetics, pathogenesis, and treatment in an effort to establish a framework for lupus nephritis management that is patient-specific and oriented toward maintaining long-term kidney function in patients with lupus...
November 7, 2016: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/27055518/gastrointestinal-manifestations-in-systemic-lupus-erythematosus
#10
M Fawzy, A Edrees, H Okasha, A El Ashmaui, G Ragab
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement, including the gastrointestinal (GI) tract. There is a significant variation in the clinical presentation and severity of GI disorders. When GI symptoms present as the initial manifestation of SLE, there is likely to be a delay in the diagnosis. The cause of these GI manifestations in SLE may be the disease, or the side effects of medications, or infections. In this study we investigated the GI manifestations in a group of SLE patients...
April 6, 2016: Lupus
https://www.readbyqxmd.com/read/27703051/application-of-slicc-classification-criteria-in-undifferentiated-connective-tissue-disease-and-evolution-in-systemic-lupus-erythematosus-analysis-of-a-large-monocentric-cohort-with-a-long-term-follow-up
#11
A Bortoluzzi, F Furini, F Campanaro, M Govoni
OBJECTIVES: The objectives of this study were to analyse the performance of the Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria for systemic lupus erythematosus (SLE) in a large cohort of undifferentiated connective tissue disease (UCTD) population at onset of the disease and during a long-term follow-up of 15 years (1999-2013) and to evaluate the transition from UCTD to SLE, according to American College of Rheumatology (ACR) 1997 and SLICC 2012 classification criteria...
October 4, 2016: Lupus
https://www.readbyqxmd.com/read/27744358/diagnosing-and-attributing-neuropsychiatric-events-to-systemic-lupus-erythematosus-time-to-untie-the-gordian-knot
#12
REVIEW
Sen Hee Tay, Anselm Mak
Neurological and psychiatric syndromes, collectively referred to as NPSLE, occur frequently in SLE. The frequency of NPSLE varies from 21 to 95%; however, only 13-38% of neuropsychiatric (NP) events could be attributable to SLE in the NPSLE SLICC inception cohort. This variability in the frequency of NPSLE is attributable to the low specificity of the ACR case definitions for SLE-attributed NP syndromes, inclusion of minor NP events in the ACR nomenclature, difficulty in ascertainment of NP events and diverse experience of rheumatologists in the clinical assessment of NP events...
October 15, 2016: Rheumatology
https://www.readbyqxmd.com/read/27744359/distinguishing-infections-vs-flares-in-patients-with-systemic-lupus-erythematosus
#13
REVIEW
Fabio E Ospina, Alex Echeverri, Diana Zambrano, Juan-Pablo Suso, Javier Martínez-Blanco, Carlos A Cañas, Gabriel J Tobón
SLE is a chronic autoimmune disease involving multiple systems. Patients with SLE are highly susceptible to infections due to the combined effects of their immunosuppressive therapy and the abnormalities of the immune system that the disease itself causes, which can increase mortality in these patients. The differentiation of SLE activity and infection in a febrile patient with SLE is extremely difficult. Activity indexes are useful to identify patients with lupus flares but some clinical and biological abnormalities may, however, make it difficult to differentiate flares from infection...
October 15, 2016: Rheumatology
https://www.readbyqxmd.com/read/27461045/the-diagnosis-and-management-of-the-haematologic-manifestations-of-lupus
#14
Alba Velo-García, Sara Guerreiro Castro, David A Isenberg
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe. Therefore, different treatment approaches are needed from simply keeping vigilant to significant immunosuppression. Most treatment evidence is based on case-reports or small retrospective studies, as few randomized controlled trials have been performed. The development of biological therapy has opened new possible ways to treat the most severe cases but further clinical trials are necessary...
July 22, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27703052/disseminated-cytomegalovirus-infection-complicating-active-treatment-of-systemic-lupus-erythematosus-an-emerging-problem
#15
N Berman, H M Belmont
Patients with systemic lupus erythematosus (SLE) often require immunosuppression to induce remission of active disease exacerbations. Over the past two decades, treatment modalities for this condition have emerged leading to improved morbidity from disease related outcomes. However, as a result, infection risks and patterns have changed, leading to higher rates of opportunistic infections among this population. We report four cases of cytomegalovirus (CMV) in patients with SLE who received immunosuppressive therapy, including pulse steroids, antimetabolites such as mycophenolate mofetil, and alkylating agents such as cyclophosphamide...
October 4, 2016: Lupus
https://www.readbyqxmd.com/read/27548593/systemic-lupus-erythematosus-primary-care-approach-to-diagnosis-and-management
#16
Nguyet-Cam Vu Lam, Maria V Ghetu, Marzena L Bieniek
Systemic lupus erythematosus is an autoimmune disease that affects many systems, including the skin, musculoskeletal, renal, neuropsychiatric, hematologic, cardiovascular, pulmonary, and reproductive systems. Family physicians should be familiar with the manifestations of lupus to aid in early diagnosis, monitoring patients with mild disease, recognizing warning signs that require referral to a rheumatologist, and helping to monitor disease activity and treatment in patients with moderate to severe disease...
August 15, 2016: American Family Physician
https://www.readbyqxmd.com/read/27687029/urinary-sediment-suggests-lupus-nephritis-histology
#17
M U Martínez-Martínez, L M de G Llamazares-Azuara, D Martínez-Galla, P B Mandeville, F Valadez-Castillo, S Román-Acosta, J A Borjas-García, C Abud-Mendoza
OBJECTIVES: The objective of this paper was to evaluate correlations between kidney biopsy indexes (activity and chronicity) and urinary sediment findings; the secondary objective was to find which components of urinary sediment can discriminate proliferative from other classes of lupus nephritis. METHODS: Lupus nephritis patients scheduled for a kidney biopsy were included in our study. The morning before the kidney biopsy, we took urine samples from each patient...
September 29, 2016: Lupus
https://www.readbyqxmd.com/read/27558659/the-global-burden-of-sle-prevalence-health-disparities-and-socioeconomic-impact
#18
REVIEW
Erin E Carter, Susan G Barr, Ann E Clarke
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can potentially lead to serious organ complications and even death. Its global burden - in terms of incidence and prevalence, differential impact on populations, economic costs and capacity to compromise health-related quality of life - remains incompletely understood. The reported worldwide incidence and prevalence of SLE vary considerably; this variation is probably attributable to a variety of factors, including ethnic and geographic differences in the populations being studied, the definition of SLE applied, and the methods of case identification...
October 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27481038/shrinking-lung-syndrome-associated-with-systemic-lupus-erythematosus-a-multicenter-collaborative-study-of-15-new-cases-and-a-review-of-the-155-cases-in-the-literature-focusing-on-treatment-response-and-long-term-outcomes
#19
REVIEW
Loïc Duron, Fleur Cohen-Aubart, Elisabeth Diot, Raphaël Borie, Sébastien Abad, Christophe Richez, Christopher Banse, Olivier Vittecoq, David Saadoun, Julien Haroche, Zahir Amoura
INTRODUCTION: Shrinking lung syndrome (SLS) is a rare respiratory manifestation of systemic lupus erythematosus (SLE), characterized by dyspnea, chest pain, elevated hemidiaphragm and a restrictive pattern on pulmonary function tests. Here, we report 15 new observations of SLS during SLE and provide a systematic literature review. We studied the clinical, biological, functional and morphologic characteristics, the treatments used and their efficacy. METHODS: The inclusion criteria were all patients with SLE defined by the American College of Rheumatology criteria Hochberg (1997) , associated with a restrictive pattern on pulmonary function tests...
October 2016: Autoimmunity Reviews
https://www.readbyqxmd.com/read/27623861/risk-of-serious-infections-with-immunosuppressive-drugs-and-glucocorticoids-for-lupus-nephritis-a-systematic-review-and-network-meta-analysis
#20
Jasvinder A Singh, Alomgir Hossain, Ahmed Kotb, George Wells
BACKGROUND: To perform a systematic review and network meta-analysis (NMA) to compare the risk of serious infections with immunosuppressive medications and glucocorticoids in lupus nephritis. METHODS: A trained librarian performed two searches: (1) PubMed for all lupus nephritis trials from the end dates for the systematic review for the 2012 American College of Rheumatology (ACR) lupus nephritis treatment guidelines and the 2012 Cochrane Systematic Review on treatments for lupus nephritis, to September 2013; and (2) PubMed and SCOPUS for all lupus trials (excluding lupus nephritis) from inception to February 2014, to obtain additional trials for harms data in any lupus patient...
2016: BMC Medicine
label_collection
label_collection
6416
1
2
2016-09-30 12:28:14
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"